Home About Science Investors & Partners Our people News & Events Careers Contact us Investors & Partners BLOCKING TUMOUR EVOLUTION 7 Our investors Our partners Our partners Artios’ strategy is to work with the foremost DDR researchers globally to identify and develop the best DDR programmes. The Company has developed strong partnerships that enable it to accelerate identification and development of novel DDR inhibitors. Through collaboration and in-licensing opportunities Artios has built an exciting portfolio of DDR programmes. Working with world leaders in DNA repair research, including Professor Simon Boulton at the Francis Crick Institute, London, the Company is able to rapidly identify the biology and clinical positioning of DDR targets for the benefit of cancer patients. Research collaboration agreements with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK) and Masaryk University in the Czech Republic have allowed access to a number of first-in-class DDR programmes. Under research agreements, Artios has the option to in-license further promising programmes, including collaborating with Masaryk University on the discovery of products targeting key nucleases involved in DNA repair pathways. Artios has a number of collaborations with leading DDR groups and academics from around the world giving access to research and expertise in DDR. Contact us Reach out to us. Contact us Quick links Home About Science Our team News & events Contact us Contact Telephone: +44 (0)1223 867 900 General enquiries: info@artiospharma.com Careers: HR@artiospharma.com Finance: Accounts@artiospharma.com Our career opportunities Our careers © Artios Pharma 2019 Terms & conditions | Privacy policy | Site map We use cookies to collect data, please see our privacy policy.